Trial registration {2a and 2b}. NCT04550832 16/09/2020 Clinicaltrials.gov Protocol version {3} Version 2.1 – 08.09.2021 Funding {4} This trial is funded by LegoChem Biosciences. LegoChem Biosciences will also supply the treatment with delpazolid. Author details {5a} 1LMU University Hospital...
et al. Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial. BMC Pediatr 17, 133 (2017). https://doi.org/10.1186/s12887-017-0886-9 Download citation Received14 November 2016 Accepted17 May 2017 ...
Title {1} CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer Trial registration {2a and 2b} EudraCT Number: 2014-003389-26 ISRCTN 41478539 Protocol version {3} Version 8....
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (
In this open-label, phase I clinical trial, we evaluated the safety and feasibility of surgical implantation and chronic DBS of the cerebellar DN. Overall, we found that our surgical approach and chronic stimulation was feasible and well tolerated in the target population, with no study-related ...
For this reason plantar pressure data at normal walking speed and a mid-step protocol was used (i.e. the subject was required to make at least three steps before and after contacting the Footscan [26, 27]). A trial was considered valid when the following criteria were met: (1) Subjects...
Trial protocol Supplement 2. Log file Supplement 3. eTable 1. Per protocol analysis eTable 2. Quality of life data eTable 3. Between site comparison Supplement 4. Data sharing statement 1. Das CJ, Razik A, Sharma S, Verma S. Prostate biopsy: when and how to perform. ...
Patients with PIK3CA/AKT/PTEN alterations were eligible to consent on the treatment protocol on one of two cohorts: (1) activating PIK3CA or AKT1 mutations or (2) PTEN mutation or PTEN loss (by IHC). Although central testing was offered, patients whose tumors have already been tested in a ...
To further evaluate the efficacy of M10 cell infusions, we next sought to track the changes in viral reservoir size over the course of the clinical trial. There has been substantial evidence supporting cell-associated HIV-1 RNA (CA HIV-1 RNA) as a reliable proxy for viral reservoir size23,...
Based on this work, we initiated a phase 1/2 first-in-human clinical trial to evaluate CLDN6 CAR-T cells alone and in combination with CARVac in patients with relapsed or refractory (r/r) CLDN6-positive solid tumors in a dose escalation part followed by cancer type-specific dose expansion...